HK1006081A1 - Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors - Google Patents
Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitorsInfo
- Publication number
- HK1006081A1 HK1006081A1 HK98105337A HK98105337A HK1006081A1 HK 1006081 A1 HK1006081 A1 HK 1006081A1 HK 98105337 A HK98105337 A HK 98105337A HK 98105337 A HK98105337 A HK 98105337A HK 1006081 A1 HK1006081 A1 HK 1006081A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mirtazapine
- pharmaceutical composition
- serotonin reuptake
- reuptake inhibitors
- selective serotonin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201703 | 1996-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1006081A1 true HK1006081A1 (en) | 1999-02-12 |
Family
ID=8224094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98105337A HK1006081A1 (en) | 1996-06-19 | 1998-06-16 | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
Country Status (25)
Country | Link |
---|---|
US (1) | US5977099A (de) |
JP (2) | JP4925074B2 (de) |
KR (1) | KR100481254B1 (de) |
CN (1) | CN1132581C (de) |
AR (1) | AR007609A1 (de) |
AT (1) | ATE213159T1 (de) |
AU (1) | AU727851B2 (de) |
BR (1) | BR9703624A (de) |
CA (1) | CA2208199C (de) |
CZ (1) | CZ290691B6 (de) |
DE (1) | DE69710390T2 (de) |
DK (1) | DK0813873T3 (de) |
ES (1) | ES2172744T3 (de) |
HK (1) | HK1006081A1 (de) |
HU (1) | HU225534B1 (de) |
ID (1) | ID17051A (de) |
IL (1) | IL121076A (de) |
NO (1) | NO313177B1 (de) |
NZ (1) | NZ328113A (de) |
PL (1) | PL188520B1 (de) |
PT (1) | PT813873E (de) |
RU (1) | RU2181287C2 (de) |
SG (1) | SG60073A1 (de) |
TR (1) | TR199700522A3 (de) |
ZA (1) | ZA975335B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
CN1154495C (zh) * | 1997-11-14 | 2004-06-23 | 阿克佐诺贝尔公司 | 米氮平用于治疗睡眠性呼吸暂停的用途 |
US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
AU781221B2 (en) * | 1999-04-19 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
US6545149B2 (en) | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
MXPA02007095A (es) * | 2000-01-19 | 2003-04-14 | Akzo Nobel Nv | Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina. |
AU2002212888A1 (en) * | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
EP1442133B1 (de) * | 2001-02-12 | 2007-12-12 | N.V. Organon | Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind. |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
CN1989968B (zh) * | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
AU2004233846B2 (en) | 2003-04-29 | 2010-07-01 | Nalpropion Pharmaceuticals Llc | Compositions for affecting weight loss |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
WO2005023767A2 (en) | 2003-09-10 | 2005-03-17 | Brentwood Equities Ltd. | Diastereomers of 4-aryloxy-3-hydroxypiperidines |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
JP5569949B2 (ja) * | 2004-11-19 | 2014-08-13 | エム・エス・ディー・オス・ベー・フェー | うつ病を治療するための、選択的セロトニン再取り込み阻害剤およびグルココルチコイド受容体拮抗薬を含む薬物組み合わせ |
EP3132792B1 (de) | 2005-11-22 | 2019-09-11 | Nalpropion Pharmaceuticals, Inc. | Zusammensetzung und verfahren zur erhöhung der insulinempfindlichkeit |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
JP2010509367A (ja) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 積層製剤 |
KR20090090316A (ko) | 2006-11-09 | 2009-08-25 | 오렉시젠 세러퓨틱스 인크. | 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법 |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
CN101332193B (zh) * | 2007-06-29 | 2012-12-12 | 杭州民生药业有限公司 | 一种马来酸氟伏沙明药物组合物的制备方法 |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
CN102459769B (zh) | 2009-06-09 | 2014-03-26 | 住友重机械工业株式会社 | 混合式挖土机及其控制方法 |
US8785453B2 (en) * | 2009-11-13 | 2014-07-22 | Green Cross Corporation | Arylpiperazine-containing purine derivatives and uses thereof |
AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
CN102000334B (zh) * | 2010-10-15 | 2012-02-22 | 北京大学 | 用于治疗抑郁症的复方制剂 |
RU2475235C2 (ru) * | 2011-03-15 | 2013-02-20 | Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" | Фармацевтическая композиция для профилактики и лечения депрессивных состояний |
JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
KR20210012056A (ko) | 2012-06-06 | 2021-02-02 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
AU8770282A (en) * | 1981-08-27 | 1983-03-03 | Shaun R. Coughlin | Composition for the treatment of atherosclerosis |
US4940585A (en) * | 1989-02-17 | 1990-07-10 | Hapworth William E | Method for the treatment of nicotine withdrawal syndrome |
US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
ATE99943T1 (de) * | 1989-12-06 | 1994-01-15 | Akzo Nv | Psychotropische wirkstoffe enthaltende stabilisierte loesungen. |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
TW587938B (en) * | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
ATE232384T1 (de) * | 1997-10-03 | 2003-02-15 | Cary Medical Corp | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion |
-
1997
- 1997-06-13 IL IL12107697A patent/IL121076A/xx not_active IP Right Cessation
- 1997-06-16 SG SG1997002068A patent/SG60073A1/en unknown
- 1997-06-16 US US08/876,346 patent/US5977099A/en not_active Expired - Fee Related
- 1997-06-17 ZA ZA9705335A patent/ZA975335B/xx unknown
- 1997-06-17 DE DE69710390T patent/DE69710390T2/de not_active Expired - Fee Related
- 1997-06-17 NZ NZ328113A patent/NZ328113A/en unknown
- 1997-06-17 CZ CZ19971870A patent/CZ290691B6/cs not_active IP Right Cessation
- 1997-06-17 PT PT97201853T patent/PT813873E/pt unknown
- 1997-06-17 ES ES97201853T patent/ES2172744T3/es not_active Expired - Lifetime
- 1997-06-17 AT AT97201853T patent/ATE213159T1/de not_active IP Right Cessation
- 1997-06-17 DK DK97201853T patent/DK0813873T3/da active
- 1997-06-18 KR KR1019970025307A patent/KR100481254B1/ko not_active IP Right Cessation
- 1997-06-18 BR BR9703624A patent/BR9703624A/pt not_active Application Discontinuation
- 1997-06-18 PL PL97320628A patent/PL188520B1/pl not_active IP Right Cessation
- 1997-06-18 HU HU9701068A patent/HU225534B1/hu not_active IP Right Cessation
- 1997-06-18 CA CA002208199A patent/CA2208199C/en not_active Expired - Fee Related
- 1997-06-18 NO NO19972816A patent/NO313177B1/no unknown
- 1997-06-18 RU RU97110083/14A patent/RU2181287C2/ru not_active IP Right Cessation
- 1997-06-19 ID IDP972117A patent/ID17051A/id unknown
- 1997-06-19 CN CN97115549A patent/CN1132581C/zh not_active Expired - Fee Related
- 1997-06-19 JP JP16257697A patent/JP4925074B2/ja not_active Expired - Fee Related
- 1997-06-19 TR TR97/00522A patent/TR199700522A3/tr unknown
- 1997-06-19 AR ARP970102687A patent/AR007609A1/es active IP Right Grant
- 1997-06-19 AU AU26129/97A patent/AU727851B2/en not_active Ceased
-
1998
- 1998-06-16 HK HK98105337A patent/HK1006081A1/xx not_active IP Right Cessation
-
2008
- 2008-12-12 JP JP2008317326A patent/JP2009137970A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL121076A0 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
IL147246A0 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
HUP0200355A2 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0103884A3 (en) | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use | |
IL122447A0 (en) | Pharmaceutical composition with anaestheric effect | |
HUP9904694A3 (en) | Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them | |
HUP0004561A3 (en) | Dihydrobenzofurans, pharmaceutical compositions containing them and use thereof | |
HUP9802132A3 (en) | Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them | |
HU9700955D0 (en) | Substituted 2-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them | |
IL140742A0 (en) | Raloxifene and pharmaceutical composition comprising the same | |
NZ331461A (en) | Benzothiophenes, formulations containing same, and methods | |
HUP0000203A3 (en) | Naphthyl derivatives, pharmaceutical compositions containing them and intermediates | |
AU1193199A (en) | Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists | |
HUP9802590A3 (en) | Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them | |
GB9623962D0 (en) | Pharmaceutical composition | |
HU9700954D0 (en) | Substituted 1-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them | |
HUP0103006A3 (en) | Substituted betha-diketones, pharmaceutical compositions containing them and their use | |
HU9602190D0 (en) | Pharmaceutical composition against poultry coccidiosis | |
HUP9904402A3 (en) | Polyhydroxyphenol derivatives, their use and pharmaceutical compositions containing them | |
IL121798A0 (en) | 1-carba-(dethia)-cephalosporin derivatives their manufacture and pharmaceutical compositions containing them | |
ZA200110325B (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same. | |
HUP9903500A3 (en) | Thiophene-, furane- and pyrrolesulfonamides, their use and pharmaceutical compositions containing them | |
GB9604426D0 (en) | Pharmaceutical composition and use thereof | |
GB9620048D0 (en) | Pharmaceutical composition | |
ZA962792B (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090617 |